BDA Partners is pleased to announce Avance Clinical, advised by Allier Capital in conjunction with BDA Partners, has received an investment from The Riverside Company (\u201cRiverside\u201d), to support further expansion of its clinical trials business. The investment amount was not disclosed.<\/p>\n\n\n\n
Avance Clinical is the largest premium Australian Contract Research Organisation (CRO). It provides global regulatory standard clinical research services across all phases to the local and international biopharma industry.<\/p>\n\n\n\n
The company is also accredited as a gene technology CRO under the Office of the Gene Technology Regulator (OGTR) which has allowed it to expand into clinical trials for vaccines and GMO therapies.<\/p>\n\n\n\n
Yvonne Lungershausen, CEO of Avance Clinical, said: \u201cWith the support of Riverside and its powerful global footprint and deep healthcare experience, Avance Clinical will execute on its regional and international expansion plans organically and via acquisitions.\u201d<\/p>\n\n\n\n
Nick Speer, Partner of Riverside, said: \u201cWe were highly attracted to Avance\u2019s leading management team who have secured blue chip customers from across the globe, providing them with world class services. Riverside brings decades of global life sciences experience, which we will leverage to further support Avance\u2019s growth objectives, with a particular focus on North America and Asia.\u201d<\/p>\n\n\n\n
Andrew Huntley, Managing Partner & Head of Healthcare at BDA Partners, commented: \u201cWe are very pleased to have helped Avance Clinical on this exciting strategic investment. BDA has built a strong track record in the healthcare sector over the last two years in Asia. This is a great demonstration of our expertise and network in the CRO and clinical trials space.\u201d<\/p>\n","protected":false},"featured_media":11983,"template":"","class_list":["post-11978","transaction","type-transaction","status-publish","has-post-thumbnail","hentry"],"acf":[],"yoast_head":"\n